<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422965</url>
  </required_header>
  <id_info>
    <org_study_id>OCTAMaratoTV3ICOF</org_study_id>
    <nct_id>NCT03422965</nct_id>
  </id_info>
  <brief_title>Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus</brief_title>
  <official_title>Evaluation of Microvascular Changes in the Perifoveal Vascular Network Using Optical Coherence Tomography Angiography (OCT-A) in Type I Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació La Marató de TV3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is directed to evaluate the role of Optical Coherence Tomography Angiography
      (OCT-A) in the evaluation of the perifoveal vascular network in type 1 diabetic patients, and
      to investigate the relationship between OCT-A-derived parameters and demographic and clinical
      factors, as metabolic control and duration of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy (DR) is the leading cause of blindness in type 1 Diabetes Mellitus (DM)
      patients, as a consequence of impaired blood flow in the retina. Optical coherence tomography
      angiography (OCT-A) is a newly developed, non-invasive, retinal imaging technique that allows
      detection of perfused and non perfused areas of the retina without the injection of dye. This
      OCT-based method permits adequate delineation of the perifoveal vascular network, and allows
      objective identification of microvascular changes, such as capillary dilation or presence of
      microaneurisms. It is also capable to detect paramacular areas of capillary non perfusion
      and/or enlargement of the foveal avascular zone (FAZ), representing an excellent tool for
      assessment of diabetic retinopathy.

      Given that all these features are commonly seen in diabetic patients, the relationship of
      these microvascular changes with systemic factors such as metabolic control or duration of
      the disease still need to be elucidated. Interestingly, further studies are required to
      investigate whether these changes reflect those occurring elsewhere in the body affected by
      diabetic microvascular disease, as the kidneys or the brain. If these relationships were
      demonstrated, early detection of these microvascular changes could lead to modifications in
      the pharmacological management of diabetic patients, as a way to reduce the risk of future
      complications in both the eye and other organs. The aim of this study is to evaluate the role
      of OCT-A in the evaluation of the perifoveal vascular network in type 1 diabetic patients,
      and to investigate the relationship between these OCT-A-derived parameters and demographic
      and clinical factors, as metabolic control and duration of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perifoveal vessel density</measure>
    <time_frame>24 months</time_frame>
    <description>OCTA images will be processed to obtain vascular density measurements in this area (mm-1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parafoveal vessel density</measure>
    <time_frame>24 months</time_frame>
    <description>OCTA images will be processed to obtain vascular density measurements in this area (mm-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Avascular Area</measure>
    <time_frame>24 months</time_frame>
    <description>OCTA images will be processed to obtain total avascular area measurements (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foveal Avascular Zone</measure>
    <time_frame>24 months</time_frame>
    <description>OCTA images will be processed to obtain foveal avascular zone area measurements (mm2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Retinal Vascular</condition>
  <condition>Retinal Disease</condition>
  <condition>Retinal Ischemia</condition>
  <condition>Retinal Ischaemia Due to Type 1 Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Vessels; Retina, Tortuous</condition>
  <arm_group>
    <arm_group_label>Type 1 Diabetes Mellitus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort of Type 1 DM patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Cohort of Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography Angiography</intervention_name>
    <description>Optical Coherence Tomography Angiography images capture.</description>
    <arm_group_label>Type 1 Diabetes Mellitus</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood test, systemic markers</description>
    <arm_group_label>Type 1 Diabetes Mellitus</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine test</intervention_name>
    <description>Urine test, systemic markers</description>
    <arm_group_label>Type 1 Diabetes Mellitus</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes Mellitus

          -  Healthy controls

        Exclusion Criteria:

          -  Ocular pathologies other than diabetic retinopathy (i.e. age-related macular
             degeneration, retinal vein occlusions, uveitis, glaucoma, etc.)

          -  Axial length: &lt;-6.00 to &gt;+3.00 diopters

          -  Media Opacities

          -  Unability to capture OCT images
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Zarranz-Ventura, MD PhD FEBO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Zarranz-Ventura, MD PhD FEBO</last_name>
    <phone>+34932275400</phone>
    <phone_ext>5667</phone_ext>
    <email>zarranz@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Clinic de Oftalmologia (ICOF), Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Zarranz-Ventura, MD PhD FEBO</last_name>
      <phone>+342275400</phone>
      <phone_ext>5667</phone_ext>
      <email>zarranz@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Javier Zarranz-Ventura, MD PhD FEBO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anibal Alé-Chilet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Barraso-Rodrigo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Hernandez, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristian Oliva-Parra, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus Gascón, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Sala-Puigdollers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Figueras-Roca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Adan, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes Unit, Institut Clinic de Malalties Digestives i Métaboliques (ICMDM), Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Ortega, MD PhD</last_name>
      <phone>+34932275400</phone>
      <phone_ext>3029</phone_ext>
      <email>eortega1@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Emilio Ortega, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Vinagre, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enric Esmatjes, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Song SJ, Wong TY. Current concepts in diabetic retinopathy. Diabetes Metab J. 2014 Dec;38(6):416-25. doi: 10.4093/dmj.2014.38.6.416. Review.</citation>
    <PMID>25541604</PMID>
  </reference>
  <reference>
    <citation>Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984 Apr;102(4):520-6.</citation>
    <PMID>6367724</PMID>
  </reference>
  <reference>
    <citation>Shah CA. Diabetic retinopathy: A comprehensive review. Indian J Med Sci. 2008 Dec;62(12):500-19. Review.</citation>
    <PMID>19265246</PMID>
  </reference>
  <reference>
    <citation>Roser P, Kalscheuer H, Groener JB, Lehnhoff D, Klein R, Auffarth GU, Nawroth PP, Schuett F, Rudofsky G. Diabetic Retinopathy Screening Ratio Is Improved When Using a Digital, Nonmydriatic Fundus Camera Onsite in a Diabetes Outpatient Clinic. J Diabetes Res. 2016;2016:4101890. doi: 10.1155/2016/4101890. Epub 2016 Jan 21.</citation>
    <PMID>26904690</PMID>
  </reference>
  <reference>
    <citation>Looker HC, Nyangoma SO, Cromie DT, Olson JA, Leese GP, Philip S, Black MW, Doig J, Lee N, Briggs A, Hothersall EJ, Morris AD, Lindsay RS, McKnight JA, Pearson DW, Sattar NA, Wild SH, McKeigue P, Colhoun HM; Scottish Diabetes Research Network (SDRN) Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia. 2013 Aug;56(8):1716-25. doi: 10.1007/s00125-013-2928-7. Epub 2013 May 21.</citation>
    <PMID>23689796</PMID>
  </reference>
  <reference>
    <citation>Zimmer-Galler IE, Kimura AE, Gupta S. Diabetic retinopathy screening and the use of telemedicine. Curr Opin Ophthalmol. 2015 May;26(3):167-72. doi: 10.1097/ICU.0000000000000142. Review.</citation>
    <PMID>25759962</PMID>
  </reference>
  <reference>
    <citation>Gass JD. A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. IV. Diabetic retinal angiopathy. Arch Ophthalmol. 1968 Nov;80(5):583-91.</citation>
    <PMID>5684307</PMID>
  </reference>
  <reference>
    <citation>Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996 Dec;39(12):1569-76.</citation>
    <PMID>8960844</PMID>
  </reference>
  <reference>
    <citation>Kwiterovich KA, Maguire MG, Murphy RP, Schachat AP, Bressler NM, Bressler SB, Fine SL. Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. Ophthalmology. 1991 Jul;98(7):1139-42.</citation>
    <PMID>1891225</PMID>
  </reference>
  <reference>
    <citation>Yeung L, Lima VC, Garcia P, Landa G, Rosen RB. Correlation between spectral domain optical coherence tomography findings and fluorescein angiography patterns in diabetic macular edema. Ophthalmology. 2009 Jun;116(6):1158-67. doi: 10.1016/j.ophtha.2008.12.063. Epub 2009 Apr 23.</citation>
    <PMID>19395034</PMID>
  </reference>
  <reference>
    <citation>Jia Y, Tan O, Tokayer J, Potsaid B, Wang Y, Liu JJ, Kraus MF, Subhash H, Fujimoto JG, Hornegger J, Huang D. Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express. 2012 Feb 13;20(4):4710-25. doi: 10.1364/OE.20.004710.</citation>
    <PMID>22418228</PMID>
  </reference>
  <reference>
    <citation>Jia Y, Bailey ST, Hwang TS, McClintic SM, Gao SS, Pennesi ME, Flaxel CJ, Lauer AK, Wilson DJ, Hornegger J, Fujimoto JG, Huang D. Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye. Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2395-402. doi: 10.1073/pnas.1500185112. Epub 2015 Apr 20.</citation>
    <PMID>25897021</PMID>
  </reference>
  <reference>
    <citation>Ishibazawa A, Nagaoka T, Takahashi A, Omae T, Tani T, Sogawa K, Yokota H, Yoshida A. Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study. Am J Ophthalmol. 2015 Jul;160(1):35-44.e1. doi: 10.1016/j.ajo.2015.04.021. Epub 2015 Apr 18.</citation>
    <PMID>25896459</PMID>
  </reference>
  <reference>
    <citation>de Carlo TE, Chin AT, Bonini Filho MA, Adhi M, Branchini L, Salz DA, Baumal CR, Crawford C, Reichel E, Witkin AJ, Duker JS, Waheed NK. DETECTION OF MICROVASCULAR CHANGES IN EYES OF PATIENTS WITH DIABETES BUT NOT CLINICAL DIABETIC RETINOPATHY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2015 Nov;35(11):2364-70. doi: 10.1097/IAE.0000000000000882.</citation>
    <PMID>26469537</PMID>
  </reference>
  <reference>
    <citation>Takase N, Nozaki M, Kato A, Ozeki H, Yoshida M, Ogura Y. ENLARGEMENT OF FOVEAL AVASCULAR ZONE IN DIABETIC EYES EVALUATED BY EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2015 Nov;35(11):2377-83. doi: 10.1097/IAE.0000000000000849.</citation>
    <PMID>26457396</PMID>
  </reference>
  <reference>
    <citation>Hwang TS, Gao SS, Liu L, Lauer AK, Bailey ST, Flaxel CJ, Wilson DJ, Huang D, Jia Y. Automated Quantification of Capillary Nonperfusion Using Optical Coherence Tomography Angiography in Diabetic Retinopathy. JAMA Ophthalmol. 2016 Apr;134(4):367-73. doi: 10.1001/jamaophthalmol.2015.5658.</citation>
    <PMID>26795548</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Javier Zarranz-Ventura</investigator_full_name>
    <investigator_title>MD, PhD, FEBO</investigator_title>
  </responsible_party>
  <keyword>Retina</keyword>
  <keyword>OCT</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Optical Coherence Tomography Angiography</keyword>
  <keyword>Systemic</keyword>
  <keyword>Blood</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

